|
US5164410A
(en)
|
1988-01-09 |
1992-11-17 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
PH26256A
(en)
|
1988-08-12 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
Oxaspiro [2,5] octane derivative
|
|
KR0138530B1
(ko)
|
1988-09-01 |
1998-05-15 |
우메모또 요시마사 |
푸마길롤 유도체
|
|
US5180738A
(en)
|
1988-09-01 |
1993-01-19 |
Takeda Chemical Industries |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
US5166172A
(en)
|
1988-09-01 |
1992-11-24 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
DE69001187T2
(de)
|
1989-03-06 |
1993-07-08 |
Takeda Chemical Industries Ltd |
6-epifumagillole, ihre herstellung und ihre verwendung.
|
|
US5288722A
(en)
|
1989-03-06 |
1994-02-22 |
Takeda Chemical Industries, Ltd. |
6-amino-6-desoxyfumagillols, production and use thereof
|
|
US5290807A
(en)
|
1989-08-10 |
1994-03-01 |
Children's Medical Center Corporation |
Method for regressing angiogenesis using o-substituted fumagillol derivatives
|
|
US6017954A
(en)
*
|
1989-08-10 |
2000-01-25 |
Children's Medical Center Corp. |
Method of treating tumors using O-substituted fumagillol derivatives
|
|
EP0415294A3
(en)
|
1989-08-31 |
1991-06-12 |
Takeda Chemical Industries, Ltd. |
Cyclohexanol derivatives, production and use thereof
|
|
TW282399B
(2)
|
1990-05-25 |
1996-08-01 |
Takeda Pharm Industry Co Ltd |
|
|
ATE205092T1
(de)
|
1992-01-30 |
2001-09-15 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
|
|
EP0602586B1
(en)
|
1992-12-16 |
1997-06-04 |
Takeda Chemical Industries, Ltd. |
Stable pharmaceutical composition of fumagillol derivatives
|
|
US5900431A
(en)
|
1995-03-27 |
1999-05-04 |
Sanofi |
Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
|
|
CA2234401A1
(en)
|
1995-10-11 |
1997-04-17 |
Fujisawa Pharmaceutical Co., Ltd. |
Vascular permeation inhibitor
|
|
EP0799616A1
(en)
|
1996-04-01 |
1997-10-08 |
Takeda Chemical Industries, Ltd. |
Oral composition comprising a fumagillol derivative
|
|
AU3968597A
(en)
|
1996-08-02 |
1998-02-25 |
Children's Medical Center Corporation |
Method of regulating the female reproductive system through angiogenesis inhibitors
|
|
WO1998056372A1
(en)
|
1997-06-09 |
1998-12-17 |
Massachusetts Institute Of Technology |
TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
|
|
US6306819B1
(en)
|
1997-10-31 |
2001-10-23 |
Massachusetts Institute Of Technology |
Method for regulating size of vascularized normal tissue
|
|
KR100357541B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
5-데메톡시 푸마질롤 유도체 및 그 제조방법
|
|
KR100357542B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
푸마질롤 유도체 및 그 제조방법
|
|
JP2000116337A
(ja)
|
1998-10-09 |
2000-04-25 |
Nippon Shokuhin Kako Co Ltd |
ペットフード
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
EP1177176B1
(en)
|
1999-04-28 |
2006-04-19 |
Aventis Pharma Deutschland GmbH |
Tri-aryl acid derivatives as ppar receptor ligands
|
|
US6323228B1
(en)
|
2000-09-15 |
2001-11-27 |
Abbott Laboratories |
3-substituted indole angiogenesis inhibitors
|
|
US6548477B1
(en)
|
2000-11-01 |
2003-04-15 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
BR0115109A
(pt)
|
2000-11-01 |
2005-10-18 |
Praecis Pharm Inc |
Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
|
|
JP2004525942A
(ja)
|
2001-03-29 |
2004-08-26 |
スミスクライン・ビーチャム・コーポレイション |
化合物および方法
|
|
EP1436286B1
(en)
|
2001-09-27 |
2009-08-19 |
Equispharm Co., Ltd. |
Fumagillol derivatives and preparing method thereof
|
|
US6803382B2
(en)
|
2001-11-09 |
2004-10-12 |
Galderma Research & Development, S.N.C. |
Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
|
|
KR100451485B1
(ko)
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
US6989392B2
(en)
|
2002-06-18 |
2006-01-24 |
Abbott Laboratories |
2-Aminoquinolines as melanin concentrating hormone receptor antagonists
|
|
US20040067266A1
(en)
|
2002-10-07 |
2004-04-08 |
Toppo Frank R. |
Weight loss compound
|
|
US20040157836A1
(en)
|
2002-10-08 |
2004-08-12 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040204472A1
(en)
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
|
WO2005066197A2
(en)
*
|
2003-12-29 |
2005-07-21 |
Praecis Pharmaceuticals, Inc. |
Inhibitors of methionine aminopeptidase-2 and uses thereof
|
|
KR100552043B1
(ko)
|
2004-02-28 |
2006-02-20 |
주식회사종근당 |
푸마질롤 유도체를 포함하는 비만치료용 조성물
|
|
EP1781303A4
(en)
|
2004-06-30 |
2008-07-02 |
Combinatorx Inc |
METHOD AND REAGENTS FOR THE TREATMENT OF METABOLISM DISEASES
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
CN101142210A
(zh)
|
2005-01-26 |
2008-03-12 |
株式会社钟根堂 |
烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物
|
|
FR2886855B1
(fr)
|
2005-06-08 |
2009-07-17 |
Agronomique Inst Nat Rech |
Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
|
|
US20070078172A1
(en)
|
2005-06-16 |
2007-04-05 |
Jenrin Discovery |
Mao-b inhibitors useful for treating obesity
|
|
EP2170402B1
(en)
*
|
2007-06-26 |
2015-03-25 |
Children's Medical Center Corporation |
Metap-2 inhibitor polymersomes for therapeutic administration
|
|
EP2217283A2
(en)
|
2007-11-28 |
2010-08-18 |
Mersana Therapeutics, Inc. |
Biocompatible biodegradable fumagillin analog conjugates
|
|
US8865746B2
(en)
|
2008-07-18 |
2014-10-21 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
ES2641471T3
(es)
|
2008-10-06 |
2017-11-10 |
The Johns Hopkins University |
Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
|
|
WO2010065877A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
US20120010290A1
(en)
|
2008-12-04 |
2012-01-12 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US8642650B2
(en)
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
WO2010065881A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
CA2777108A1
(en)
|
2009-10-09 |
2011-04-14 |
Zafgen Corporation |
Sulphone compounds and methods of making and using same
|
|
US20130210821A1
(en)
|
2010-05-27 |
2013-08-15 |
James E. Vath |
Methods for Treating Obesity
|
|
CN103249735B
(zh)
|
2010-07-22 |
2016-04-06 |
扎夫根股份有限公司 |
三环化合物及其制备和使用方法
|
|
US9221787B2
(en)
|
2010-10-12 |
2015-12-29 |
Zafgen, Inc. |
Sulphonamine compounds and methods of making and using same
|
|
WO2012074968A1
(en)
|
2010-11-29 |
2012-06-07 |
Zafgen Corporation |
Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
|
|
WO2012075026A1
(en)
|
2010-11-29 |
2012-06-07 |
Zafgen Corporation |
Methods of treating obesity using an effective dose of a metap-2 inhibitor
|
|
US9173865B2
(en)
|
2010-11-29 |
2015-11-03 |
Zafgen, Inc. |
Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
|
|
MX344238B
(es)
|
2011-01-26 |
2016-12-07 |
Zafgen Inc |
Compuestos de tetrazol y métodos para preparar y usar los mismos.
|
|
EP2683706B1
(en)
|
2011-03-08 |
2018-02-21 |
Zafgen, Inc. |
Oxaspiro [2.5]octane derivatives and analogs
|
|
BR112013028666A2
(pt)
|
2011-05-06 |
2017-08-08 |
Zafgen Inc |
compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
|
|
CN103764641B
(zh)
|
2011-05-06 |
2016-10-26 |
扎夫根股份有限公司 |
部分饱和的三环化合物及其制备和使用方法
|
|
EP2705036B1
(en)
|
2011-05-06 |
2015-08-12 |
Zafgen Inc. |
Tricyclic sulfonamide compounds and methods of making and using same
|